v-2.jpg

Press Releases and News

Blue Line.png

November 7th, 2022 - A recent study by Vanderbilt investigators with initial support provided by Amytrx Therapeutics demonstrated the molecular control of inflammation in an experimental mouse model of atopic dermatitis (AD) ….. read more

Blue Line.png

June 30, 2022 - Amytrx Works with AmbioPharm to Manufacture Its Phase I/II Atopic Dermatitis Asset; August Bioservices, Tergus Pharma Tasked for Topical Formulation... read more

Blue Line.png

June 9, 2022 - Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis... read more

Blue Line.png

May 26, 2022 - Two years post-stealth exit, highly secretive inflammation biotech secures final tranche of Series A round... read more

Blue Line.png

May 25, 2022 - Amytrx Therapeutics Raises $18M for New AD Treatment... read more

Blue Line.png

October 21, 2021 - Amtryx Therapeutics is featured in Pharma's Almanac 'The Road to 50 States' Interviews... read more

Blue Line.png

June 8, 2021 - VUMC team develops potential treatment for life-threatening microbial inflammation...read more

Blue Line.png

October 27, 2020 - Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment...read more

Blue Line.png

October 19, 2020 - CEOCFO Magazine Interview with Amytrx CEO About Advancing the Next Generation of Inflammation-Targeting Therapies: AMTX-100 Technology delivers First-in-Class Biologically Active Molecule to Treat Chronic Diseases Mediated by Inflammation...read more

Blue Line.png

October 8, 2020 - Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis...read more

Blue Line.png

September 17, 2020 - Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications....read more